Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Do patients with neutropenic sepsis need granulocyte stimulating factor (GCSF)?

Thomas Coventry and Faisal Azam
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.16-3-s8
Clin Med June 2016
Thomas Coventry
Wrexham Maelor Hospital, Wrexham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Faisal Azam
Wrexham Maelor Hospital, Wrexham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Aims

We performed this review to assess the prescribing practice of therapeutic granulocyte stimulating factor (GCSF) in patients admitted with neutropenic sepsis (NS) after systemic anticancer therapy (SACT) at ‘local hospital’.

NS is defined as neutrophil count of ≤0.5 and temperature of ≥38°C. Therapeutic GCSF in the treatment of NS has a limited role. ASCO (American Society of Clinical Oncology), EORTC (European Organisation for Research and Treatment of Cancer) and NICE (National Institute for Health and Care Excellence) guidelines recommend it for patients with febrile neutropenia and high risk of infection-associated complications.

Methods

Retrospective analysis of case notes of patients, admitted with NS from January to December 2012, after treatment with SACT for solid tumours, was performed.

Indications defined by the guidelines are:

  • Fever ≤38°C + neutrophil count <0.1 g/L after SACT

AND at least one of the following:

  • aim of the of SACT (palliative for progressive disease)

  • hypotension on admission

  • clinical or radiological signs of pneumonia

  • duration of neutropenia (>10 days)

  • age (>65 years)

  • organ dysfunction/failure

  • proven invasive fungal infection.

Results

Total numbers of patients admitted with NS were 54.43 (80%) patients were female. Mean age was 58 years. Breast cancer was the commonest tumour, with 23 (42%) patients followed by lung cancer (n = 7, 13%). Mean neutrophil count on admission was 0.61 g/L (range: 0.01–3.1 g/L). Average length of stay was 6 days (1–24). 42 (77%) patients had a temperature of <37.5°C on admission and 23 (43%) patients had a neutrophil count of >0.5 g/L.

GCSF was administered in 46 (94%) patients. Nine patients were already on prophylactic GCSF at the time of admission, while 37 (68%) were started in the hospital with a therapeutic intention.

Among the 37 patients who received therapeutic GCSF, it was only indicated in four (12%) patients as per guidelines. The other 33 (88%) patients had therapeutic GCSF with no indications. Median number of days on GCSF were 3 (range 1–7) and total number of GCSF injections were 124. 97 out of 124 GCSF injections were administered without any defined indications.

Conclusions

Most of the therapeutic GCSF prescriptions were not evidence based. It was indicated and administered appropriately in 12% of patients. Among the patients who received therapeutic GCSF for the treatment of NS, 88% were not indicated.

GCSF has a limited role in the treatment of SACT-induced NS. Appropriate prescribing will prevent unnecessary side effects, cost and nurse/pharmacy time.

  • © Royal College of Physicians 2016. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Do patients with neutropenic sepsis need granulocyte stimulating factor (GCSF)?
Thomas Coventry, Faisal Azam
Clinical Medicine Jun 2016, 16 (Suppl 3) s8; DOI: 10.7861/clinmedicine.16-3-s8

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Do patients with neutropenic sepsis need granulocyte stimulating factor (GCSF)?
Thomas Coventry, Faisal Azam
Clinical Medicine Jun 2016, 16 (Suppl 3) s8; DOI: 10.7861/clinmedicine.16-3-s8
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aims
    • Methods
    • Results
    • Conclusions
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Catheter-related bloodstream infections in adults receiving parenteral nutrition: does the time taken to report blood cultures impact on clinical management?
  • One in a million
  • Identifying barriers perceived by young adults with type 1 diabetes for wellbeing coach-supported self-care for their diabetes
Show more Clinical

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians